FLT3 and chronic myelomonocytic leukemia: Additionally, initial experience with quizartinib in combination with chemotherapy in younger [84] and older patients with newly diagnosed AML [85] and in combination with azacytidine or low-dose cytarabine in older patients with newly diagnosed FLT3-ITD-mutated AML and those with FLT3-ITD-mutated AML in first relapse (including myelodysplastic syndromes and chronic myelomonocytic leukemia) [86] indicated that the combinations were feasible and appeared effective in both younger and older patients.